# About Meds Retatrutide — Independent Research Digest > About Meds Retatrutide — an independent editorial project summarizing the published retatrutide research literature. Not a clinic, pharmacy, or vendor. An independent editorial project. Not a clinic, not a pharmacy, not a vendor. ## What this site is Meds Retatrutide is an independent editorial project that publishes summaries of the peer-reviewed and clinical-trial research literature on retatrutide (LY3437943). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science. The site is organized around the published trial record: Phase 1b pharmacokinetics, Phase 2 obesity and type 2 diabetes outcomes, the MASLD liver-fat substudy, structural biology, and the ongoing TRIUMPH Phase 3 program. Every quantitative claim is cited to a specific study in the references list. The "meds" in the domain name is an SEO artifact reflecting the search terms people use when looking for information about this investigational compound. The content is a literature digest — not a prescription service, not a telehealth platform, not a source of retatrutide in any form. ## Why this site exists Retatrutide is among the most closely watched investigational compounds in metabolic medicine. The Phase 2 data — published in the New England Journal of Medicine and The Lancet — attracted unusually wide lay attention, and search interest in the compound is high and growing. Much of what circulates online combines accurate trial data with vendor-driven framing or community anecdotes presented as clinical findings. This site exists to offer a different reading: the trial data as the trials actually reported it, with the limitations stated plainly, the safety cautions front and center, and the investigational status never buried. A reader who finishes this digest should have a clear picture of what Phase 2 showed, what it didn't show, and what the Phase 3 program is designed to determine. No person connected with this site has any financial interest in retatrutide's approval, any relationship with Eli Lilly, or any involvement in the gray-market research chemical trade. ## Editorial standards Every quantitative claim on this site is sourced to a specific study in the [retatrutide references](/references) list. We do not cite claims that do not appear in the published literature. We do not use competitor brand names — only INN/USAN generic compound names appear here. We do not write human dosing recommendations or use prescriptive language. The compound's investigational status is not a footnote on this site — it is the context for every page. Retatrutide is not approved anywhere. It does not treat or cure anything in a regulatory or clinical sense — the trials studied what it did in enrolled populations, and we describe exactly that. Community-reported effects on the [effects page](/effects) are labeled anecdotal, segregated from clinical trial findings, and carry no dose information. ## Contact Editorial inquiries can be submitted via the [contact page](/contact). We respond to factual corrections supported by published literature. We do not respond to vendor inquiries, procurement requests, or requests for clinical guidance. --- A plain-spoken reading of the retatrutide trial record — what Phase 2 measured, what Phase 3 is designed to determine, and what remains genuinely open; not a clinic, not a pharmacy, not a vendor.